Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil

Investigational New Drugs

Volumn 30, Issue 4, 2012, Pages 1641-1645

  Florin, Valerie ^a   Desmedt, Eve ^a   Vercambre Darras, Sophie ^a   Mortier, Laurent ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

5 fluorouracil; Imiquimod; Melanoma; Skin metastases; Tumor immunology

Indexed keywords

FLUOROURACIL; IMIQUIMOD;

AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG EFFICACY; DRUG RESPONSE; EVENING DOSAGE; FEMALE; FOLLOW UP; HUMAN; MALE; MELANOMA; MORNING DOSAGE; PRIORITY JOURNAL; SKIN METASTASIS; TUMOR RECURRENCE;

ADMINISTRATION, TOPICAL; AGED; AGED, 80 AND OVER; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FLUOROURACIL; HUMANS; MELANOMA; NEOPLASM METASTASIS; SKIN NEOPLASMS; SKIN ULCER; TREATMENT OUTCOME;

EID: 84866744027     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9717-2     Document Type: Article

References (20)

1. Rosenberg SA, Rapp HJ (1976) Intralesional immunotherapy of melanoma with BCG. Med Clin North Am 60:419-430
2. Radny P, Caroli UM, Bauer J, Paul T, Schlegel C, Eigentler TK, Weide B, Schwarz M, Garbe C (2003) Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer 89:1620-1626
3. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N Engl J Med 363:711-723
4. Love WE, Bernhard JD, Bordeaux JS (2009) Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol 145:1431-1438
5. Ahmed I, Berth-Jones J (2000) Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol 143:843-845
6. Steinmann A, Funk JO, Schuler G, von den Driesch P (2000) Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol 43:555-556
7. Wolf IH, Smolle J, Binder B, Cerroni L, Richtig E, Kerl H (2003) Topical imiquimod in the treatment of metastatic melanoma to skin. Arch Dermatol 139:273-276
8. Bong AB, Bonnekoh B, Franke I, Schön MP, Ulrich J, Gollnick H (2002) Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology 205:135-138
9. Green DS, Bodman-Smith MD, Dalgleish AG, Fischer MD (2007) Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Br J Dermatol 156:337-345
10. Goette DK (1981) Topical chemotherapy with 5-fluorouracil. A review. J Am Acad Dermatol 4:633-649
11. Ondo AL, Mings SM, Pestak RM, Shanler SD (2006) Topical combination therapy for cutaneous squamous cell carcinoma in situ with 5-fluorouracil cream and imiquimod cream in patients who have failed topical monotherapy. J Am Acad Dermatol 55:1092-1094
12. Makower D, Wadler S (1999) Interferons as biomodulators of fluoropyrimidines in the treatment of colorectal cancer. Semin Oncol 26:663-671
13. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S (2002) Small antiviral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3:196-200
14. Wagner TL, Ahonen CL, Couture AM, Gibson SJ, Miller RL, Smith RM, Reiter MJ, Vasilakos JP, Tomai MA (1999) Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell Immunol 191:10-19
15. Schön MP, Wienrich BG, Drewniok C, Bong AB, Eberle J, Geilen CC, Gollnick H, Schön M (2004) Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod. J Invest Dermatol 122:1266-1276
16. Hesling C, D'Incan M, Mansard S, Franck F, Corbin-Duval A, Chèvenet C, Déchelotte P, Madelmont JC, Veyre A, Souteyrand P, Bignon YJ (2004) In vivo and in situ modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases. Br J Dermatol 150:761-767
17. Powell AM, Robson AM, Russell-Jones R, Barlow RJ (2009) Imiquimod and lentigo maligna: a search for prognostic features in a clinicopathological study with long-term follow-up. Br J Dermatol 160:994-998
18. Stefanaki C, Nicolaidou E, Hadjivassiliou M, Antoniou C, Katsambas A (2006) Imiquimod-induced vitiligo in a patient with genital warts. J Eur Acad Dermatol Venereol 20:755-756
19. Gowda S, Tillman DK, Fitzpatrick JE, Gaspari AA, Goldenberg G (2009) Imiquimod-induced vitiligo after treatment of nodular basal cell carcinoma. J Cutan Pathol 36:878-881
20. Mashiah J, Brenner S (2008) Possible mechanisms in the induction of vitiligo-like hypopigmentation by topical imiquimod. Clin Exp Dermatol 33:74-76